Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Inhibition
11%
AZD2171
11%
Cediranib
100%
Dose-response
11%
Drug Class
11%
Early Detection
11%
Early Management
11%
Epithelial Ovarian Cancer
11%
Growth Factor Receptor Signaling
11%
Hypertension
100%
Older Patients
11%
Phase II Study
11%
Proteinuria
100%
Rapid Development
100%
Renal Toxicity
11%
Signal Transduction Inhibitors
11%
Systolic BP
22%
Toxicity Management
11%
Twice Daily
11%
Urinalysis
11%
Vascular Endothelial Growth Factor Inhibitors
11%
Vascular Endothelial Growth Factor Receptor (VEGFR)
11%
Vascular Endothelial Growth Factor Receptor Inhibitor
100%
Vasodilation
11%
Women Age
11%
Medicine and Dentistry
Cediranib
100%
Cell Signaling Pathway
11%
Clinician
11%
Dose Response
11%
Krukenberg Tumor
11%
Nephrotoxicity
11%
Oral
100%
Proteinuria
100%
Urinalysis
11%
Vasculotropin Inhibitor
11%
Vasculotropin Receptor
100%
Vasodilatation
11%
Biochemistry, Genetics and Molecular Biology
Cediranib
100%
Dose Response
20%
Growth Factor Receptor Inhibitor
100%
Vascular Endothelial Growth Factor
20%
Vasodilatation
20%
VEGF Receptors
100%
Agricultural and Biological Sciences
Dose Response
11%
Nephrotoxicity
11%
Ovarian Cancer
11%
Ovary Cancer
11%
Proteinuria
100%
Urinalysis
11%
Vascular Endothelial Growth Factor
11%
Vascular Endothelial Growth Factor Receptors
100%